{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:05:53Z","timestamp":1774292753666,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.clml.2020.03.009","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T21:12:54Z","timestamp":1584652374000},"page":"563-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma"],"prefix":"10.1016","volume":"20","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.03.009_bib1","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.03.009_bib2","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib3","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/annonc\/mds177","article-title":"Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up","volume":"23","author":"Colombat","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2015.61.3968","article-title":"Rituximab maintenance for a maximum of\u00a05 years after single-agent rituximab induction in follicular lymphoma: results of\u00a0the randomized controlled phase III trial SAKK 35\/03","volume":"34","author":"Taverna","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib5","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin\u2019s lymphoma: results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002770000163","article-title":"IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group","volume":"79","author":"Feuring-Buske","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.03.009_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2141.2000.01965.x","article-title":"A\u00a0UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response","volume":"109","author":"Foran","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.03.009_bib8","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib9","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/annonc\/mdr620","article-title":"Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness","volume":"23","author":"Czuczman","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib10","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.28299","article-title":"A\u00a0phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701","volume":"119","author":"Grant","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.03.009_bib11","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.03.009_bib12","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.03.009_bib13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in\u00a0vitro and in\u00a0vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.03.009_bib14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.03.009_bib15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4 (CRBN)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.03.009_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.14866","article-title":"Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell\u2013mediated cytotoxicity","volume":"179","author":"Hagner","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.03.009_bib17","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.03.009_bib19","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib20","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bjh.12008","article-title":"Single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences","volume":"159","author":"Eve","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.03.009_bib22","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with\u00a0mantle-cell lymphoma who relapsed or progressed after or were refractory to\u00a0bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib23","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trneny","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib25","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1002\/ajh.24854","article-title":"Long-term analysis of phase II studies of single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma","volume":"92","author":"Witzig","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.03.009_bib26","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.03.009_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in\u00a0vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.03.009_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.03.009_bib29","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib30","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1093\/annonc\/mdx496","article-title":"A\u00a0phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin\u2019s lymphoma (NHL): CALGB 50803 (Alliance)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib31","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","article-title":"Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy","volume":"134","author":"Zucca","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.03.009_bib33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib34","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib35","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.03.009_bib37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.03.009_bib38","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib39","series-title":"Revlimid EMA product information","year":"2019"},{"key":"10.1016\/j.clml.2020.03.009_bib40","series-title":"Revlimid: package insert","year":"2019"},{"key":"10.1016\/j.clml.2020.03.009_bib41","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial","volume":"185","author":"Becnel","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.03.009_bib42","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.03.009_bib43","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-14-2221","article-title":"Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas","volume":"21","author":"Chong","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.03.009_bib44","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open label phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib45","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.3324\/haematol.2015.131144","article-title":"Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma","volume":"100","author":"Fowler","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.03.009_bib46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","article-title":"A\u00a0phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma","volume":"129","author":"Kiesewetter","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.03.009_bib47","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.3324\/haematol.2015.139329","article-title":"Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi","volume":"101","author":"Sacchi","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.03.009_bib48","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2008.20.3737","article-title":"Erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysis in lenalidomide-treated patients","volume":"27","author":"Castaneda","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib49","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/0018578717717394","article-title":"Highly probable drug reaction with eosinophilia and systemic symptoms syndrome associated with lenalidomide","volume":"52","author":"Shanbhag","year":"2017","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.clml.2020.03.009_bib50","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/blood-2016-06-718106","article-title":"Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103","volume":"128","author":"Ujjani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.03.009_bib51","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/j.clml.2017.03.082","article-title":"Diarrhea incidence in multiple myeloma patients treated with lenalidomide and pomalidomide","volume":"17","author":"Montefusco","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.03.009_bib52","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1182\/blood.V124.21.5779.5779","article-title":"Colesevelam hydrochloride for the treatment of lenalidomide induced diarrhea","volume":"124","author":"Watson","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2020.03.009_bib53","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S0049-3848(16)30103-7","article-title":"Update of thrombosis in multiple myeloma","volume":"140","author":"Leebeek","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.clml.2020.03.009_bib54","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/bloodadvances.2018016683","article-title":"Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis","volume":"2","author":"Yamshon","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2020.03.009_bib55","doi-asserted-by":"crossref","first-page":"e18258","DOI":"10.1200\/JCO.2017.35.15_suppl.e18258","article-title":"Tumor flare reaction (TFR) in cancer treatments: a systematic review","volume":"35","author":"Taleb","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib56","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.03.009_bib57","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/CAD.0000000000000814","article-title":"Tumour flare reaction in cancer treatments: a comprehensive literature review","volume":"30","author":"Taleb","year":"2019","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clml.2020.03.009_bib58","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/cncr.25748","article-title":"Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response","volume":"117","author":"Chanan-Khan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.03.009_bib59","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1634\/theoncologist.2017-0055","article-title":"Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents","volume":"22","author":"Cheson","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.03.009_bib60","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:36Z","timestamp":1761870936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020301427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2152265020301427"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.03.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}